RePORT International Resources

TAG’s Cheat Sheets for Tuberculosis Activists are designed to help advocates navigate the range of tools in use and in the research pipeline.

To accompany the updated Activist’s Guide to Shorter Treatment for Drug-Resistant Tuberculosis, TAG also developed three additional educational materials to support community-based and civil society organizations leading treatment literacy, peer support, and community-led monitoring activities:

The World Health Organization (WHO) guidelines for diagnosing TB have evolved along with available technologies and tools that are increasingly accurate, simple, and efficient at detecting TB and resistance to a wider range of TB drugs. Despite this progress, 2.7 million individuals with TB still remain undiagnosed and undetected. On July 17th, 2025, TAG hosted a community webinar on tests for TB and drug resistance. The webinar breaks down the latest WHO guidelines and explores the most effective tools for diagnosing TB and drug resistance. The webinar also launched TAG’s updated resource, An Activist’s Guide to Diagnostic Tools for Tuberculosis, and provides a deep dive into two sections of the Guide: (1) the array of WHO-recommended diagnostic tools and how they should be optimally used in country programs; and (2) key access considerations and actions activists can take to ensure that all people at risk of TB receive quality TB diagnostic testing.

From Forest to Factory: Tracing the Supply Chains for Two Modern Adjuvants of Global Health Importance — QS-21 and MPL provides a first-of-its-kind analysis of the global supply chains of two key adjuvants used in several of the world’s most important vaccines. QS-21 and MPL are part of licensed vaccines against malaria, shingles, and respiratory syncytial virus, and in a promising candidate vaccine for tuberculosis (TB) called M72/AS01E.

What Could Go Right: Vital Partnerships with Communities and Civil Society for New Tuberculosis Vaccines, written together with community partners and supported by Wellcome, explores the indispensable role of communities and civil society in preparing the way for new TB vaccines and ensuring their success once they become available.

The Tuberculosis Data, Impact Assessment and Communications Hub (TB DIAH) supports decision-makers by generating, analyzing, and utilizing quality data to inform and scale up effective TB services. This website provides resources on TB M&E and surveillance processes.

A report has been published based on findings of the study conducted in Ukraine: “Studying the Aspects of Gender, Equity, and Inclusion in the Workplace Among Healthcare Professionals Involved in TB Response" https://tbcoalition.eu/resource/files/2025/09/report-on-gender-assessment-among-healthcare-workers-in-ukraine_eng.pdf The aim of the study was to assess the level of implementation of gender equality principles among healthcare workers providing TB diagnostic and treatment services, and to examine the barriers preventing women and men from exercising their right to gender equality. The study employed a triangulation method, which ensured the validity and reliability of the results. As part of this approach, the following methods were used: Desk review, In-depth interviews, Focus group discussions.

National Association of Tuberculosis Patients of the Republic of Moldova “SMIT” published a report with the results of the study ‚ Multidimensional Analysis of Tuberculosis-Related Stigma in the Republic of Moldova. The study was conducted at the request of the National TB Response Program, with the support of the Center for Health Policies and Studies and the TB Europe Coalition, and funded by the Global Fund to Fight AIDS, Tuberculosis and Malaria and the Stop TB Partnership. The assessment was conducted in 2025 and provides a structured analysis of the barriers to accessing human rights-based, gender-sensitive, and population-specific TB care.

This website features TBEC's resources ranging from different publications to various capacity building tools such CSOs map or TBEC webinar recordings, please see below a short overview of different international and regional institutions and organisations, fighting against TB in the WHO Europe region and globally. All of the websites contain valuable sources of information and capacity building tools that you will find helpful in your advocacy in the WHO Europe region and globally.

TBEC’s mission is to strengthen the role and contribution of civil society organisations (CSOs) and affected communities within a sustainable and effective response to TB across in the region by: Providing a coordinating body that unites TB advocates across the region, in order to disseminate information, promote collaboration and learning, and share best practice; Building the advocacy capacity and coordinate the strategies of TB advocates and CSOs across the region; Leveraging the political and financial commitment

Treatment Action Group (TAG) and the Community Research Advisors Group (CRAG) released the TB Representative Studies Rubric (TB RSR), a new tool that community advisory boards (CABs) can use when designing and reviewing clinical trials protocols. The TB RSR is a 17-item questionnaire that assesses whether TB treatment trials include the types of people who get TB. By documenting the representativeness of TB studies, community advisors and researchers can work together to ensure that all people in need of safe and effective options for treating and preventing TB can benefit from research.

This catalog provides a listing of each course, seminar series, and other training modalities offered by each TRAC that are open to the TB community. Just as a university or college course catalog is divided into the offerings provided by a given department, the TRAC Train catalog lists the virtual, hybrid, and in-person seminar series, journal clubs, classes/workshops, and other events that are offered by each TRAC.

A three-part online study club series, hosted by the Diagnostics Equity Consortium (DEC) and the Global TB Community Advisory Board (TB CAB), explores the evolving TB diagnostic landscape and strategies to expand testing coverage. Session one addresses the TB testing gap and emerging diagnostic tools. Session two focuses on optimizing national diagnostic networks and test distribution. Session three examines the impact and trade-offs of near- and point-of-care TB tests in expanding access.

TBnet is a European grass-root consortium consisting of health care professionals and scientists, aimed at promoting quality of care for tuberculosis patients by addressing health-inequalities, providing expert guidance in areas where clinical evidence is missing, defining research priorities, conducting multicenter clinical studies, and training early career European clinicians and scientists.

This webinar recording from TB Net occurred in July 2025.

Implementation research (IR) is important for designing strategies or solutions to overcome bottlenecks that prevent proven and innovative public health interventions from reaching the people who need them. This ensure that these interventions are used in a manner that results in the outcome for which they were intended. Such solutions include how to overcome barriers to adoption of drugs, diagnostics or preventive measures that improve health for people at risk of malaria, tuberculosis, NTDs or other infectious diseases. IR can help to ensure that health solutions reach the people who need them and are used in ways that generate intended results. This course is a step-by-step online training for public health researchers and decision-makers, disease control programme managers, academics and others that focuses on how to design and demonstrate robust IR projects to improve control of infectious diseases of poverty and generate better health outcomes.

TDR supports effective and innovative global health research, through strengthening the research capacity of disease-affected countries, and promoting the translation of evidence into interventions that reduce the burden of infectious diseases and build resilience in the most vulnerable populations

TDR's catalogue of online courses in implementation research (IR)

Can assess all the 13th IAS Conference on HIV Science at this website

The Antibacterial Resistance Leadership Group (ARLG) invites requests for industry collaboration from the ARLG in the form of advice, guidance, protocol design for drug, device, or diagnostic development. The ARLG develops, designs, implements, and manages a clinical research agenda to increase knowledge of antibacterial resistance (AR). The ARLG aims to advance research by building transformational trials that will change clinical practice and reduce the impact of antibacterial resistance and antimicrobial resistance through the following strategies: - Early clinical evaluation of new antibacterials; - Comparative effectiveness or efficacy trials; - Strategy trials to optimize currently licensed antibacterials (dose, duration, need for drug) to reduce the risk of resistance; - Clinical algorithm testing strategies; - Treatment-based prevention measures; - Diagnostics testing in the context of treatment trials, epidemiologic elements, or behavioral modification; - Effective infection control programs which include surveillance for resistant organisms, outbreak investigation, and antibiotic stewardship to prevent the development and spread of resistant organisms; - Novel facilities level activities to prevent the development of resistance.